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ABSTRACT 
Background and Objectives: Clopidogrel resistance or low-responsiveness may be associated with recurrent ath-
erothrombotic events after drug-eluting stent (DES) implantation. We prospectively evaluated the association be-
tween clopidogrel resistance assessed by the Verifynow
TM P2Y12 assay (Accumetrics, San Diego, CA, USA) and 
stent thrombosis (ST) or cardiac death (CD) in patients with acute coronary syndrome (ACS) within 6 months 
after DES implantation. Subjects and Methods: We enrolled 237 consecutive patients (160 males, 65.2±10.3 
years) with ACS who received a DES implantation. The composite endpoint was defined to CD or ST by Acade-
mic Research Consortium definitions within 6 months post-implantation. Clopidogrel resistance was defined as 
<20% inhibition of the P2Y12 receptor. Results: Baseline demographic characteristics were similar between 142 
normal individuals and 95 clopidogrel resistant patients. CD occurred in one case (0.7%) in the normal group 
and two cases (2.13%) in the resistant group (p=0.344). There was no episode of ST in the normal group and four 
episodes in the resistant group (4.2%, four definite ST) (p=0.035). Univariate logistic regression revealed an ad-
justed odds ratio (OR) for composite end point of CD or ST of 9.646 {95% confidence interval (CI) 1.139-
81.679}, and multivariate logistic regression for composite end point revealed an OR of 12.074 (95% CI 1.205-
120.992). Conclusion: Clopidogrel low-responsiveness assessed by the Verifynow
TM P 2Y12 assay is an indepen-
dent predictor of ST and composite end point of ST or CD in patients with ACS within 6 months after DES 
implantation. (Korean Circ J 2009;39:512-518) 
 





Six months following percutaneous coronary artery 
intervention (PCI), coronary angiography has revealed 
a re-stenosis rate of 30-40% in patients treated using 
balloon dilatation and 20-30% in those treated using 
a bare metal stent.
1)2) In recent years, use of drug-elut-
ing stents (DESs) has lowered the re-stenosis rate by 
<10%, and the need for repeated PCI due to re-steno-
sis has also declined, which have prompted the marked 
increase in the use of DESs.
3) PCI is also performed in 
cases in which there are small-sized, long lesions, as well 
as for treatment of multivessel diseases.
4-6) In recent years, 
however, the occurrence of stent thrombosis (ST) as-
sociated with DESs has been increasingly reported. ST 
can prelude a poor outcome such a acute myocardial in-
farction (MI) or sudden cardiac death (CD).
7) In an ac-
tual clinical setting, the frequency has been reported to 
be higher than that reported on well-designed large-
scale clinical trials. Furthermore, an association of ST 
and early discontinuation of antiplatelet agents has 
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been reported. The United States Food and Drug Ad-
ministration has recommended that antiplatelet agents 
such as aspirin or clopidogrel be used for at least one 
year following the use of a DES.
8-10)  
Recent studies have shown that anti-platelet responses 
to aspirin and clopidogrel vary depending on patients. 
In the studies, appropriate anti-platelet responses were 
not achieved in 5-45% of patients taking aspirin or 4-
30% of those taking clopidogrel.
11-14) In the study, ap-
proximately 25% of patients with ST-segment elevat-
ion MI had a resistance to clopidogrel, in whom the in-
cidence of cardiovascular complications has been re-
ported to increase after a 6-month period.
15-17) 
Methods for measuring clopidogrel resistance include 
light transmittance aggregometry (LTA), vasodilator-sti-
mulated phosphoprotein (VASP) phosphorylation as-
say, use of the Platelet Function Analyzer-100
TM and 
the Verify-Now
TM P2Y12 assay (Accumetrics, San Diego, 
CA, USA). LTA is a standardized measurement me-
thod, but it cannot be generally used because special 
training is needed and its manipulation is complicated. 
By contrast, the point-of-care VerifyNow
TM P2Y12 assay 
is a simpler means of measurement that produces re-
sults nearly identical to those of LTA, prompting its 
widespread use.
18-20) Many studies have shown that pa-
tients with LTA-determined clopidogrel resistance are 
at greater risk for cardiovascular death (CVD) follow-
ing PCI using a DES.
17)21-24) However, the relationship 
between CVD and clopidogrel resistance measured us-
ing the VerifyNow
TM P2Y12 assay is unclear, and is com-
pletely unknown in patients with acute coronary syn-
drome (ACS).  
Presently, we attempted to examine the effect of clo-
pidogrel resistance measured using the VerifyNow
TM 
P2Y12 assay on ST or CD within 6 months following the 
procedure in patients with ACS who underwent PCI 
using a DES. 
 
Subjects and Methods 
 
Study population 
The current study was a single-center, prospective, 
cohort study conducted in 237 patients (age 65.2±10.3 
years, of whom 160 were male), in whom the anti-pla-
telet effects of clopidogrel were confirmed by the Ve-
rifyNow
TM P 2Y12 assay. The patients had been diag-
nosed with ACS (unstable angina or non-ST-segment 
elevated MI), and had undergone coronary angiogra-
phy involving the insertion of a DES due to >50% cor-
onary artery stenosis. All procedures were conducted 
at the Department of Cardiology, Wonju Christian Hos-
pital, from January 2006 to December 2007. Exclusion 
criteria were renal failure, presence of an infectious dis-
ease, left ventricular ejection fraction <30%, malignant 
neoplasm, hepatic failure, previous long-term use of anti-
coagulation drugs, history of hemorrhagic disease and 




Specimen sampling and measurement   
For the assessment of clopidogrel responsiveness, sam-
ples were collected from the vein following PCI and 5 
days after initiating regular administration of clopido-
grel (75 mg). Each sample was placed in a tube contain-
ing 3.2% citrate and clopidogrel resistance was assess-
ed within 8 hours. Sampling was done in the hospital 
for patients who were continually hospitalized during 
this period or during the first follow-up for patients who 
had been discharged. Clopidogrel resistance was deter-
mined as detailed below.   
 
Determination of clopidogrel resistance 
Clopidogrel non-response (resistance) is considered 
to be a degree of responsiveness ≤10%, while semi-
res-ponse ranges from 11% to <30%.
26)27) Resistance 
can also be determined with the value corresponding to 
the 4th quartile based on four quartiles.
17)  
In a preliminary study conducted at Wonju Chris-
tian Hospital, 500 patients were tested. The inhibition 
rate (% inhibition) for P2Y12 receptor was 20%, which 
corresponded to the value of the 4th quartile. Accord-
ingly, in the current study, patients whose inhibition 
rate for P2Y12 receptor was <20% were determined to 
have a clopidogrel resistance. For cases in which the res-
ponses to clopidogrel were assessed using the Verify-
Now
TM system, an inhibition rate for the P2Y12 recep-
tor  ≥20% was defined as the normal control group 
(normal response) and otherwise cases were defined as 
the resistance group (low response). Currently, there are 
no established guidelines for the treatment of resistance 
group. Therefore, clopidogrel was continually used and 
was not replaced by other drugs. 
 
Endpoint 
The primary endpoint was ST or CD that occurred 
6 months following the insertion of a DES. The com-
posite end point was cases in which ST or CD occurred. 
 
Definition of stent thrombosis 
ST was classified as ‘definite’, ‘probable’ and ‘possible’ 
according to the definition of Academic Research Con-
sortium (ARC). Based on the phase, it was also classi-
fied as acute, subacute or late. Definite ST was defined 
in patients who displayed ischemic chest pain and its 
concurrent presence with acute ischemic change in an 
electrocardiogram, and patients who showed an elevat-
ed level of the cardiac enzymes in cases in which an in-
complete or complete obstruction of the blood vessels 
were present due to the presence of in-stent thrombosis  
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on coronary angiography. Probable ST was defined as 
a diagnosis of MI confirmed around the area of stent 
insertion or in cases in which death due to an unknown 
cause occurred within 30 days post-PCI. Possible ST 
was defined as cases in which idiopathic sudden death 
occurred within 30 days post-PCI. Acute, subacute and 
late ST were defined as cases in which ST occurred wi-
thin 24 hours, 1 day-1 month and more than one month 
following PCI, respectively. 
 
Stent insertion and drug therapy 
For a stent insertion, after the radial or femoral ar-
tery was punctured, a 6-7 Fr sheath was inserted. Th-
rough an arterial sheath, a catheter was inserted. All the 
procedures were performed using a catheter and a guide 
wire. In most cases, a stent insertion was performed for 
cases in which the remaining stenosis was present fol-
lowing a balloon dilatation of the coronary artery. A 
determination on stent insertion was wholly dependent 
on the subjective judgment of clinicians. Successful st-
ent insertion was defined as cases in which residual ste-
nosis was <30% following stent insertion. In cases in 
which a residual stenosis remained following a stent 
insertion, with the additional use of a balloon dilata-
tion, the procedures were performed in such a manner 
as to minimize the residual stenosis. Prior to stent in-
sertion, all the patients received a pre-treatment using 
600 mg clopidogrel and 300 mg aspirin. In patients 
who received a DES, 100 mg aspirin was administered 
for life and 75 mg clopidogrel was administered for at 
least 6 months in principle. 
 
Statistical analysis 
Data is expressed as mean±standard deviation. Sta-
tistical analysis was performed using Statistical Package 
for Social Science (SPSS) software for Windows, version 
12.0 (SPSS Inc., Chicago, IL, USA). The current study 
examined the frequency of ST. The Chi-square test and 
Fisher’s exact test assessed whether the frequency of ST 
would vary depending on the responsiveness of recep-
tor to clopidogrel. To analyze the odds ratio (OR) of de-
veloping ST and CD, binary logistric regression and a 
multivariable logistic regression were used. A p of <0.05 





Of patients with ACS who received a DES, the anti-
platelet effects of clopidogrel were measured using the 
VerifyNow
TM P 2Y12 assay in 237 patients (65.2±10.3 
years, including 160 male patients). Of the 142 patients 
of the normal control group (63.9±10.9 years, includ-
ing 94 male patients), 43 (30.3%) had a non-ST-seg-
ment elevation MI and the remaining patients had an 
unstable angina. Of the 95 patients defined with clo-
pidogrel resistance (64.8±11.1 years, including 66 male 
patients), 32 (33.7%) had a non-ST-segment elevation 
MI and the remaining patients had an unstable angina. 
There was no significant difference between the two 
groups (p=0.581). In addition, there were no significant 
differences between the groups in the number of patients 
who had MI, diabetes mellitus, hypertension, smoking 
or aspirin resistance (Table 1). There were no significant 
differences in hematologic findings between the two 
groups. But there was a significant difference in the in-
hibition rate for P2Y12 receptor and P2Y12 reaction unit 
(PRU) between the two groups (Table 2). 
 
Incidence of stent thrombosis and cardiac death 
ST never developed in the normal control group and 
occurred in four patients of the resistance group. The 
Table 1. Baseline characteristics of study patients 
  Normal response (n=142)  Low response (n=95)  p
Age (years)  63.9±10.9 64.8±11.1 0.520
Male (%)    94 (66.2)  66 (69.5)  0.598
Diagosis  NSTEMI (%)  43 (30.3)  32 (33.7)  0.581
CVA (%)  13 (9.2)0 4  (4.2)  0.144
MI (%)  15 (10.7)  4 (4.2)  0.073
DM (%)  39 (27.7)  30 (31.6)  0.516
Hypertension (%)  79 (56.0)  60 (63.2)  0.275
Risk 
Smoking (current) (%)  29 (20.6)  20 (21.1)  0.139
Previous PCI  14 (9.9)0 9  (9.6)  0.929
Target vessel (%) 
(LAD/LCX/RCA/LM)  53.2/19.4/25.9/1.4 58.9/17.9/21.1/2.1  0.777
Stent diameter (mm)  2.73±0.46 2.81±0.35 0.548
Procedure 
Stent length (mm)  28.4±10.9 29.1±18.5 0.493
Aspirin resistance (%)  6 (5.6)  08 (10.0)  0.259
Aspirin resistance: ARU ≥550 (aspirin reaction unit). NSTEMI: non-ST elevation myocardial infarction, CVA: cerebrovascular accident, 
MI: myocardial infarction, DM: diabetes mellitus, PCI: percutaneous coronary intervention, LAD: left anterior descending artery, LCX: left 
circumflex artery, RCA: right coronary artery, LM: left main    
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difference reached statistical significance (p=0.014) (Ta-
ble 3). ST in the resistance group comprised one acute 
case, one subacute case and two late cases; all were de-
finite ST. CD occurred in one patient of the normal 
control group and two patients of the resistance group, 
and was not significant (p=0.344). When the incid-
ences of ST or CD were summed, they were revealed 
in one patient of the normal control group and six pa-
tients of the resistance group. This difference reached 
statistical significance (p=0.012) (Table 3). In the resist-
ance group, there were four cases of ST and two cases 
of CD (Fig. 1). 
 
Odds ratio of stent thrombosis and cardiac death 
Univariate analysis based on a binary logistic regress-
ion analysis showed that the OR of clopidogrel resist-
ance in the development of ST or CD was 9.646 {95% 
confidence interval (CI); 1.139-81.679}. A multivariate 
analysis performed based on a multivariate logistic re-
gression analysis showed that the OR of clopidogrel re-
sistance in developing ST or CD was 12.074 (95% CI; 




The incidence of ST, which has previously been re-
ported in well-designed large-scale clinical trials was 
not relatively higher presently. ST has been reported to 
be similar to that seen following the use of a bare-metal 
stent. However, application of the results of well-design-
ed large-scale clinical trials to actual clinical settings re-
Table 2. Laboratory characteristics of study patients 
  Normal response (n=142)  Low response (n=95)  p 
Platelet (10
9/L) 264.1±81.9 254.7±79.2 0.394
Total cholesterol (mg/dL)  177.7±58.8 172.3±41.5 0.449
HDL (mg/dL)  44.3±11.4 43.0±10.8 0.400
LDL (mg/dL)  102.4±35.3 101.0±39.2 0.786
CK-MB (ng/dL)  22.5±52.1 27.0±61.2 0.549
Troponin I (ng/dL)  8.8±15.4 8.0±15.9 0.686
Cr (mg/dL)  0.95±0.54 0.95±0.83 0.991
CRP (mg/dL)  1.3±3.8 1.0±2.5 0.524
BNP (pg/dL)  142.1±356.6 99.4±151.1 0.296
ARU 433.3±64.2 455.7±66.9 0.010
PRU 183.3±124.2 288.7±63.2  <0.001
% inhibition of P2Y12 43.3±18.7 9.4±6.9  <0.001
HDL: high density lipoprotein-cholesterol, LDL: low density lipoprotein-cholesterol, CK-MB: creatine kinase MB fraction, Cr: creatinine, 
CRP: C-reactive protein, BNP: B-type natriuretic peptide, ARU: aspirin reaction unit, PRU: P2Y12 reaction unit 
 
Table 3. Difference between normal and low response of clopidogrel for stent thrombosis (ST) and cardiac death 
  All  Normal response  Low response  p
Stent thrombosis (%)  4 (1.7)  0 (0)  4 (4.2)  0.014
ST by ARC (%)         
Definite ST    4 (1.7)  0  4 (4.2)   
Probable ST  0  0  0   
Possible ST  0  0  0   
Timing of ST (%)         
Acute  1 (0.4)  0  1 (1.0)   
Subacute ST    1 (0.4)  0  1 (1.0)   
Late ST  2 (0.8)  0  2 (2.1)   
Cardiac death (%)  3 (1.3)  1 (0.7)  2 (2.1)  0.344
ST or cardiac death (%)  7 (3.0)  1 (0.7)  6 (6.3)  0.012











Normal response  Low response 
Fig. 1. Comparison of end point by % inhibition of P2Y12 receptor.
% inhibition of P2Y12 receptor  
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mains problematic. Clinical studies are mostly conduct-
ed in patients who are eligible for specific selection cri-
teria and tend to exclude unstable status of patients with 
cardiac necrosis due to thrombotic occlusion events such 
as MI, PCI performed in an emergency setting and 
presence of a complex lesion such as bifurcation lesion 
or chronic total occlusion. It can, therefore, be inferred 
that the frequency of ST will likely not be relatively hi-
gher following the use of DESs in a real world setting. 
In an actually clinical setting, it would be markedly hi-
gher than the incidence of ST, which has been report-
ed on well-designed large-scale clinical trials.
28)  
Recent studies have shown that the incidence of STs 
is increased in the clinical setting.
7,29-31) Indeed, in a real-
world setting, prognostic indicators for predicting ST 
include the early discontinuation of use of antiplatelet 
agents, renal failure, bifurcation lesion, diabetes mellitus 
and a lower level of left ventricular ejection fraction.
29) 
A recent study using intravascular ultrasound has shown 
that optimal inflation of a stent is not associated with 
prognosis.
32) It has also been reported, however, that 
incomplete inflation of a stent and a significant resi-
dual stenosis rate may be associated with the occurrence 
of ST.
33) Of these prognostic indicators, early disconti-
nuation of use of antiplatelet agents has been reported 
to play a major role. Clinically, a low clopidogrel res-
ponsiveness has a similar risk profile as compared with 
the early discontinuation of use of antiplatelet agents. 
Clopidogrel resistance measured using LTA following 
stent insertion showed a relative risk of 3.71 (95% CI; 
1.08-12.69) for CVD.
24) Clopidogrel resistance meas-
ured using Platelet Function Analyzer-100 showed a 
relative risk of 2.5 (95% CI; 1.6-3.8) for hospitalization 
due to CD and MI. In addition, clopidogrel resistance 
has been reported to play a role in achieving a long-
term prognosis as one of the independent prognostic 
indicators.
34) In a previous study that measured the re-
lationship of clopidogrel resistance determined using 
the VerifyNow
TM system, with the occurrence of CVD 
and ST in 380 patients (93.7%) with stable angina, ev-
ent-free survival was significantly lower in the resist-
ance group (91.5% vs. 99.0%, p=0.004).
35)  
The current study also measured the responsiveness 
to clopidogrel using the VerifyNow
TM system, with the 
aim of clarifying the relationship between CD and ST. 
In particular, the current study enrolled patients with 
ACS, a subject patient group for which only a small 
number of studies have been conducted, and then per-
formed a follow-up study in an outpatient setting con-
comitantly with a follow-up telephone survey. The cur-
rent study examined all the patients who were suspected 
to have a ST. Our univariate and multivariate analyses 
strongly implicate clopidogrel resistance as an indepen-
dent prognostic indicator for predicting the occurrence 
of ST or CD. These results agree with those obtained 
by LTA and the Platelet Function Analyzer-100. As 
shown in patients with stable angina, the present data 
indicates a key role for clopidogrel resistance in those 
with ACS.   
A noteworthy clinical point in the current study was 
the finding that all the cases of ST occurred within 6 
months following the procedure, during which patients 
were taking both aspirin and clopidogrel. This may in-
dicate that ST cannot be prevented using a maintenance 
therapy with aspirin and clopidogrel. For the preven-
tion of ST, the United States Food and Drug Admini-
stration recommends that a maintenance therapy with 
aspirin and clopidogrel be performed for at least 1 year 
in patients who receive a DES.
8-10) But, maintenance 
therapy might not be effective in completely prevent-
ing the occurrence of ST, with more active therapy and 
management being necessary.   
The present study has two limitations. Firstly, we 
did not completely evaluate patient-related risk factors 
of developing ST (e.g., local activity of platelet aggreg-
ation), lesion-related risk factors (e.g., length of lesions 
and characteristics of artherosclerotic plaques) and pro-
cedural risk factors (e.g., incomplete inflation of a stent). 
It could be inferred, however, that relatedness dimini-
shed lesion-related and procedure-related risk factors 
due to the common use of intravascular ultrasound and 
high pressure balloon. By contrast, it could also be in-
ferred that patient-related risk factors such as clopido-
grel resistance would assume greater importance. The 
second limitation concerns the study size; although the 
total number of enrolled patients was 273, only seven 
patients presented with ST or CD. Despite the presence 
of statistical significance, the possibility for a bias due 
Table 4. Univariable logistic regression for cardiac death or ST
  p  Relative risk*  95% CI 
Low response for clopidogrel  0.038 9.646  1.139-81.679
DM 0.026 6.668  1.251-35.541
Previous MI  0.543 2.011  0.211-19.129
Old age (>65 years)  0.331 4.127  0.237-71.901
Cr 0.907 1.063  0.385-2.934
LDL 0.534 0.994  0.973-1.014
EF 0.482 1.022  0.962-1.085
Hypertension 0.466 1.866  0.349-9.969
*adjusted variable: age and sex are included. CI: confidence in-
terval, ST: stent thrombosis, MI: myocardial infarction, DM: dia-
betes mellitus, Cr: creatinine, LDL: low density lipoprotein, EF:
ejection fraction 
 
Table 5. Multivariable logistic regression for cardiac death or ST
  p  Relative 
risk*  95% CI 
Low response for clopidogrel  0.034 12.074  1.205-120.992
DM 0.034 07.066 1.156-43.1940
*adjusted variable: age and sex are included. CI: confidence in-
terval, DM: diabetes mellitus, ST: stent thrombosis 
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to a smaller sample size cannot be excluded. 
Despite these limitations, the current study is of cli-
nical significance in that it provides a basis by which 
drug augmentation or new drugs could be used in the 
event of PCI with a DES, since risk factors of develop-
ing ST or CD using point-of-care system were stratified. 
As with other medical advances, further large-scale pro-
spective studies are necessary.   
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